{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:23:33Z","timestamp":1785813813842,"version":"3.56.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003400","name":"Ontario Ministry of Research, Innovation and Science","doi-asserted-by":"publisher","award":["Early Researcher Award"],"award-info":[{"award-number":["Early Researcher Award"]}],"id":[{"id":"10.13039\/501100003400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40273-019-00852-y","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T08:02:42Z","timestamp":1573027362000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada"],"prefix":"10.1007","volume":"38","author":[{"given":"Feng","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherilyn K. D.","family":"Houle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhd. Wasem","family":"Alsabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-0052","authenticated-orcid":false,"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"852_CR1","unstructured":"World Health Organization. Hepatitis B; 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ . Accessed 5 Apr 2018."},{"key":"852_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/ijms.2.36","volume":"2","author":"CQ Pan","year":"2005","unstructured":"Pan CQ, Zhang JX. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci. 2005;2:36\u201340.","journal-title":"Int J Med Sci"},{"key":"852_CR3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12929-015-0199-y","volume":"22","author":"J-F Wu","year":"2015","unstructured":"Wu J-F, Chang M-H. Natural history of chronic hepatitis B virus infection from infancy to adult life\u2014the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015;22:92.","journal-title":"J Biomed Sci"},{"key":"852_CR4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"ASF Lok","year":"2007","unstructured":"Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507\u201339.","journal-title":"Hepatology"},{"key":"852_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:45\u201355.","journal-title":"Hepatology"},{"key":"852_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R, Jia JD, Locarnini S, et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl C","key":"852_CR7","doi-asserted-by":"crossref","first-page":"5C","DOI":"10.1155\/2007\/910831","volume":"21","author":"M Sherman","year":"2007","unstructured":"Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007;21(Suppl C):5C\u201324C.","journal-title":"Can J Gastroenterol"},{"issue":"Suppl","key":"852_CR8","first-page":"313A","volume":"60","author":"P Marcellin","year":"2014","unstructured":"Marcellin P, Gane EJ, Flisiak R, et al. Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology. 2014;60(Suppl):313A\u20134A.","journal-title":"Hepatology"},{"key":"852_CR9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"852_CR10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"852_CR11","unstructured":"Ontario Drug Benefit. eFormulary. Prices are effective as of May 31, 2019. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/odbf_eformulary.aspx . Accessed 16 June 2019."},{"key":"852_CR12","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"852_CR13","unstructured":"Ontario Drug Policy Research Network. Hepatitis B environmental scan report; 2015. http:\/\/odprn.ca\/wp-content\/uploads\/2015\/09\/Hep-B_Environmental-scan_Sept-28-2015.pdf . Accessed 12 June 2019."},{"key":"852_CR14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jval.2012.06.005","volume":"15","author":"J He","year":"2012","unstructured":"He J, Bowen JM, Xie F, et al. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health. 2012;15:894\u2013906.","journal-title":"Value Health"},{"key":"852_CR15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2165\/11589260-000000000-00000","volume":"29","author":"H Dakin","year":"2011","unstructured":"Dakin H, Sherman M, Fung S, et al. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics. 2011;29:1075\u201391.","journal-title":"Pharmacoeconomics"},{"key":"852_CR16","unstructured":"Ontario Drug Policy Research Network. Hepatitis B Pharmacoeconomics report; 2015. http:\/\/odprn.ca\/wp-content\/uploads\/2015\/09\/Hep-B_Pecon-Report_Sept-28-2015.pdf . Accessed 6 June 2019."},{"issue":"1 Suppl","key":"852_CR17","first-page":"909A","volume":"64","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Cathcart AL, et al. No resistance to tenofovir alafenamide detected through 48 weeks of treatment in patients with chronic hepatitis B. Hepatology. 2016;64(1 Suppl):909A.","journal-title":"Hepatology"},{"key":"852_CR18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"852_CR19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012;15:812\u201320.","journal-title":"Value Health"},{"key":"852_CR20","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 4th ed.; 2017. https:\/\/www.cadth.ca\/dv\/guidelines-economic-evaluation-health-technologies-canada-4th-edition . Accessed 7 Aug 2018."},{"key":"852_CR21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/0003-4819-135-9-200111060-00006","volume":"135","author":"BJ Mcmahon","year":"2001","unstructured":"Mcmahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759\u201368.","journal-title":"Ann Intern Med"},{"key":"852_CR22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00019053-200725110-00006","volume":"25","author":"DL Veenstra","year":"2007","unstructured":"Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25:963\u201377.","journal-title":"Pharmacoeconomics"},{"key":"852_CR23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1478-3231.2011.02559.x","volume":"31","author":"WWL Wong","year":"2011","unstructured":"Wong WWL, Woo G, Jenny Heathcote E, et al. Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 2011;31:1179\u201390.","journal-title":"Liver Int"},{"key":"852_CR24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7326\/0003-4819-147-7-200710020-00004","volume":"147","author":"DW Hutton","year":"2007","unstructured":"Hutton DW, Tan D, So SK, et al. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147:460\u20139.","journal-title":"Ann Intern Med"},{"key":"852_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-142-10-200505170-00007","volume":"142","author":"F Kanwal","year":"2005","unstructured":"Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005;142:821\u201331.","journal-title":"Ann Intern Med"},{"key":"852_CR26","volume-title":"Risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with or without cirrhosis treated with oral antivirals: results of the nationwide HEPNET. Greece cohort study","author":"GV Papatheodoridis","year":"2009","unstructured":"Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with or without cirrhosis treated with oral antivirals: results of the nationwide HEPNET. Greece cohort study. Boston: AASLD; 2009."},{"key":"852_CR27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gut.2003.020263","volume":"53","author":"L Benvegn\u00f9","year":"2004","unstructured":"Benvegn\u00f9 L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744\u20139.","journal-title":"Gut"},{"key":"852_CR28","first-page":"77","volume":"21","author":"G Fattovich","year":"1995","unstructured":"Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology. 1995;21:77\u201382.","journal-title":"Hepatology"},{"key":"852_CR29","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","volume":"101","author":"F Kanwal","year":"2006","unstructured":"Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101:2076\u201389.","journal-title":"Am J Gastroenterol"},{"key":"852_CR30","first-page":"257","volume":"24","author":"A Craxi","year":"1987","unstructured":"Craxi A, Colombo P, D\u2019Amico G, et al. Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area. Ann Ist Super Sanita. 1987;24:257\u201365.","journal-title":"Ann Ist Super Sanita"},{"key":"852_CR31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","volume":"31","author":"G D\u2019Amico","year":"1986","unstructured":"D\u2019Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468\u201375.","journal-title":"Dig Dis Sci"},{"key":"852_CR32","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","volume":"97","author":"G Fattovich","year":"2002","unstructured":"Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886\u201395.","journal-title":"Am J Gastroenterol"},{"key":"852_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493\u20136.","journal-title":"Hepatology"},{"key":"852_CR34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","volume":"29","author":"S-M Lin","year":"1999","unstructured":"Lin S-M, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971\u20135.","journal-title":"Hepatology"},{"key":"852_CR35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678\u201386.","journal-title":"Gastroenterology"},{"key":"852_CR36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","volume":"27","author":"DL Veenstra","year":"2008","unstructured":"Veenstra DL, Spackman DE, Bisceglie A, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2008;27:1240\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"852_CR37","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522\u20137.","journal-title":"Hepatology"},{"key":"852_CR38","first-page":"19","volume":"16","author":"E Gigi","year":"2007","unstructured":"Gigi E, Lalla T, Orphanou E, et al. Long term follow-up of a large cohort of inactive HBsAg (+)\/ HBeAg (\u2212)\/anti-HBe (+) carriers in Greece. J Gastrointest Liver Dis. 2007;16:19\u201322.","journal-title":"J Gastrointest Liver Dis"},{"key":"852_CR39","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.9778\/cmajo.20160161","volume":"5","author":"WWL Wong","year":"2017","unstructured":"Wong WWL, Lee KM, Singh S, et al. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open. 2017;5:E97\u2013108.","journal-title":"CMAJ Open"},{"key":"852_CR40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","volume":"8","author":"WWL Wong","year":"2019","unstructured":"Wong WWL, Pechivanoglou P, Wong J, et al. Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019;8:207.","journal-title":"Syst Rev"},{"key":"#cr-split#-852_CR41.1","unstructured":"Statistics Canada. Life tables, Canada, provinces and territories 1980\/1982 to 2014\/2016"},{"key":"#cr-split#-852_CR41.2","doi-asserted-by":"crossref","unstructured":"2018. https:\/\/www150.statcan.gc.ca\/n1\/pub\/84-537-x\/84-537-x2018002-eng.htm . Accessed 23 July 2018.","DOI":"10.16992\/ASOS.14426"},{"key":"852_CR42","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1524-4733.2010.00782.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13:922\u201333.","journal-title":"Value Health"},{"key":"852_CR43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98\u2013107.","journal-title":"Hepatology"},{"key":"852_CR44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL-H Wong","year":"2013","unstructured":"Wong GL-H, Chan HL-Y, Mak CW-H, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537\u201347.","journal-title":"Hepatology"},{"key":"852_CR45","unstructured":"Canadian Institute for Health Information. Health care in Canada 2010; 2010. https:\/\/secure.cihi.ca\/free_products\/HCIC_2010_Web_e.pdf . Accessed 7 Aug 2018."},{"key":"852_CR46","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/00004836-200411003-00011","volume":"38","author":"YM Gagnon","year":"2004","unstructured":"Gagnon YM, Levy AR, Iloeje UH, et al. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol. 2004;38:S179\u201386.","journal-title":"J Clin Gastroenterol"},{"key":"852_CR47","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic review report for Vemlidy; 2018. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0537_Vemlidy_PE_Report.pdf . Accessed 16 June 2019."},{"key":"852_CR48","unstructured":"Ontario Ministry of Health and Long-Term Care. Physician Services Under the Health Insurance Act; 2015. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master20160401.pdf . Accessed 26 Sep 2018."},{"key":"852_CR49","unstructured":"Statistics Canada. Consumer price index, annual average, not seasonally adjusted; 2019. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501 . Accessed 16 June 2018."},{"key":"852_CR50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2012\/736452","volume":"26","author":"G Woo","year":"2012","unstructured":"Woo G, Tomlinson G, Yim C, et al. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol. 2012;26:445\u201351.","journal-title":"Can J Gastroenterol"},{"key":"852_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jgh.12010","volume":"28","author":"C-L Lin","year":"2013","unstructured":"Lin C-L, Kao J-H. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:10\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"852_CR52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","volume":"58","author":"M Blachier","year":"2013","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593\u2013608.","journal-title":"J Hepatol"},{"key":"852_CR53","first-page":"473","volume":"146","author":"A Laupacis","year":"1992","unstructured":"Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473\u201381.","journal-title":"CMAJ"},{"key":"852_CR54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","volume":"26","author":"C McCabe","year":"2008","unstructured":"McCabe C, Claxton K, Culyer AJ. The NICE cost effectiveness threshold: what it is and what it means. Pharmacoeconomics. 2008;26:733\u201344.","journal-title":"Pharmacoeconomics"},{"key":"852_CR55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CEOR.S16655","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Gaeta GB, Vigan\u00f2 M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res. 2011;3:37\u201346.","journal-title":"Clinicoecon Outcomes Res"},{"key":"852_CR56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12962-015-0046-8","volume":"13","author":"G Kockaya","year":"2015","unstructured":"Kockaya G, Kose A, Yenilmez FB, et al. Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Effect Resour Alloc. 2015;13:21.","journal-title":"Cost Effect Resour Alloc"},{"key":"852_CR57","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bjid.2012.12.005","volume":"17","author":"A Wiens","year":"2013","unstructured":"Wiens A, Lenzi L, Venson R, et al. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis. 2013;17:418\u201326.","journal-title":"Braz J Infect Dis"},{"key":"852_CR58","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jval.2015.05.007","volume":"18","author":"SL Bermingham","year":"2015","unstructured":"Bermingham SL, Hughes R, Fenu E, et al. Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health. 2015;18:800\u20139.","journal-title":"Value Health"},{"issue":"1","key":"852_CR59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40273-012-0009-2","volume":"31","author":"M Buti","year":"2013","unstructured":"Buti M, Oyag\u00fcez I, Lozano V, et al. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review. Pharmacoeconomics. 2013;31(1):63\u201375.","journal-title":"Pharmacoeconomics"},{"key":"852_CR60","unstructured":"World Health Organization. World hepatitis summit harnesses global momentum to eliminate viral hepatitis; 2015. http:\/\/www.who.int\/mediacentre\/news\/releases\/2015\/eliminate-viral-hepatitis\/en\/ . Accessed 28 May 2018."},{"key":"852_CR61","unstructured":"Government of Canada. Message from the Minister of Health World Hepatitis Day\u2014July 28, 2018; 2018. https:\/\/www.canada.ca\/en\/public-health\/news\/2018\/07\/message-from-the-minister-of-health-world-hepatitis-day\u2013july-28-2018.html . Accessed 11 Apr 2019."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00852-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00852-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00852-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:48:45Z","timestamp":1695394125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00852-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00852-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"6 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by an Ontario Ministry of Research, Innovation, and Science Early Researcher Award that was awarded to WW.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/Grant Support"}},{"value":"WW received a research grant from the Canadian Liver Foundation. FT, SAK, and WA declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}